Mologic

LONDON: Avacta Group has entered into a commercial partnership with Mologic Ltd to accelerate to market Avacta’s AffiDX SARS-CoV-2 lateral flow rapid antigen test. Avacta will also support antigen testing in low and middle income countries by providing access to Avacta’s spike antigen test through Mologic. The partnership will provide a faster route to market…